Skip to main content
MedPath Trial logoMedPath TrialMedPath Trial Home
Clinical Trials/JPRN-UMIN000024612
JPRN-UMIN000024612UnknownPhase 2

Clinical study for effectiveness of rituximab for acquired coagulopathy - Rituximab Trial for acquired coagulopathy

Gunma University0 sites10 target enrollmentStarted: November 1, 2016Last updated:
Share to TwitterShare to FacebookShare to LinkedInShare to Reddit
Conditions

Trial Snapshot

Phase
Phase 2
Enrollment
10
Study OverviewEligibility CriteriaInvestigatorsRecords & IdentifiersSimilar Trials

Study Overview

Brief Summary

No summary available.

Study Design

Study Type
Interventional

Eligibility Criteria

Ages
20years-old to 85years-old (—)
Sex
All

Inclusion Criteria

  • Not provided

Exclusion Criteria

  • •(1) The men that an agreement is not obtained in preventing conception during study drug dosing period. (2) The women who may be pregnant during nursing during pregnancy and the women who hope for pregnancy during study drug dosing period. (3) The patients who are proved to have an HIV antibody. (4) The patients that positive was confirmed in one or more with HBs antigen, HBs antibody, anti-hepatitis B core antigen and HCV antibody. (however, we do not do it with the subject of the exclusion by this rule when a thing with the vaccination is clear when an examination of hepatitis B is positive) (5) In addition, the patients whom doctor attending judged to be inadequate as an object of this study.

Investigators

Similar Trials

Completed
Not Applicable
A study of the efficacy and safety to rituximab in treating adult onset refractory nephrotic syndromeRefractory nephrotic syndrome
JPRN-UMIN000021143Fujita Health University School of Medicine, Department of Nephrology10
Active, not recruiting
Phase 1
Efficacy and safety of rituximab in the treatment of good prognosis microscopic polyangiitis
EUCTR2018-000637-12-FRASSISTANCE PUBLIQUE - HOPITAUX DE PARIS (AP-HP)106
Completed
Not Applicable
Rituximab therapy for refractory pemphigus
JPRN-jRCTs031180405Funakoshi Takeru20
Recruiting
Not Applicable
Safety evaluation study about rituximab therapy for refractory pemphiguspemphigus
JPRN-UMIN000026004Keio University, School of Medicine20
Completed
Not Applicable
Efficacy and safety of rituximab for patients with severe rheumatic diseaseChildhood-onset severe rheumatic disease (systemic lupus erhythematosus, dermatomyositis, poly myositis, systemic sclerosis , mixed connective tissue disease, Sjogren&#39s syndrome, anti-phospholipid syndrome)
JPRN-UMIN000018376Yokohama City University Hospital Department of Pediatrics20